Growing presence of drug-resistant tuberculosis fuels need for faster development of new combination therapies

June 6, 2012

Johns Hopkins experts in the prevention and treatment of multidrug-resistant tuberculosis are calling for increased screening and more rapid testing of the 9 million people worldwide estimated to be infected each year with TB and now at risk for this form of the highly contagious lung disease.

The call follows results of a survey showing that the harder-to-treat TB variants are much more widespread than previously thought.

Details of the survey, to be published in The online June 7, provide the first-ever, nationwide estimate of the size of the problem in China, where over a million new infections occur each year. The 2007 survey of more than 4,000 Chinese newly diagnosed or recently treated for TB showed that one in 10 was infected with drug-resistant strains of TB, more formally known as Mycobacterium tuberculosis. Among this group, some 0.5 percent (or more than 5,000, annually) were diagnosed with extensively drug- resistant TB, which the experts say is nearly incurable.

TB is spread when uninfected people inhale small numbers of coughed up and spewed into the air by people already infected. Antibiotics can cure the disease, but compliance with the lengthy course of treatment is uncertain and the drugs available in the developing world to treat the disease are limited to fewer than a dozen, mostly older medications.

In an editorial accompanying the study, Johns Hopkins infectious disease specialists Richard Chaisson, M.D., and Eric Nuermberger, M.D., call the proliferation of the drug-resistant organisms an "enormous challenge" to eradicating TB, which now kills 1.5 million people each year, mostly in the .

More worrisome among the study findings, says Chaisson, a professor at the Johns Hopkins University School of Medicine and founding director of its Center for Tuberculosis Research, was that the majority of the estimated 110,000 drug-resistant cases occurred among people newly diagnosed with TB, indicating that these drug-resistant bacteria were transmitted from one person to another. Only 3 percent of all newly detected cases were tested for drug resistance.

This research, Chaisson says, "upsets the old dogma" that drug-resistant organisms occur mostly in people who fail to respond to therapy or in infected people who relapse after drug treatment. In sum, he says, drug resistance appears to be present in new cases on a large scale, and drug-resistance testing should not be limited to previously treated patients.

Chaisson says the study also highlights the urgent need for faster testing of those newly diagnosed to determine drug resistance. Current laboratory testing methods, while relatively cheap (at less than $5 per person), take several weeks to show bacterial growth in sputum samples. Same-day results are available using high-tech molecular assays, but they dramatically raise the test cost to as much as $40 per person, a cost he says is worth it, given the "sobering" scope of the problem.

According to Chaisson, multidrug-resistant strains of TB cannot be effectively treated by either of the two most commonly used antibiotics, isoniazid and rifampin. Extensively strains do not die off in the presence of two other so-called second-line treatments, either.

Both Chaisson and Nuermberger, an associate professor at Johns Hopkins, have tested simpler, shorter regimens of new and existing antibiotics, hoping to streamline treatment and stem the spread of drug-resistant strains. The scientists say, however, that developing new antibiotics is the key to controlling TB in all its drug-resistant forms.

Results from an international study of a new antibiotic called delamanid, published in the same issue of the medical journal, are encouraging, but only "half the answer," they say. In some 400 infected people taking either varying doses of delamanid or a sugar pill in combination with older, second-line antibiotics for two months, TB bacteria were eradicated from sputum samples in at least 42 percent of those taking the new drug combination, and in only 30 percent of those taking the sugar pill version. Delamanid is manufactured by Otsuka Pharmaceutical Inc. of Rockville, Md.

Nuermberger says the delamanid study results are comparable to those published in 2009 in the same medical journal for another new antibiotic, bedaquiline, which showed that after two months of therapy, the drug eradicated sputum TB in 48 percent of study participants.

Nuermberger says the arrival of any new antibiotic drugs is good news, but he stresses that what health care providers really need is better information about what drug combination regimens work best, including guidelines about when to use the newer antibiotics, in what dose and order, and for how long.

"Just as HIV is more effectively treated with potent drug cocktails, the regimens that offer the greatest hope against TB contain two or more effective drugs," says Nuermberger, who adds that further studies need to be done to assess whether delamanid and bedaquiline work better together or separately in boosting the effects of older antibiotics.

Chaisson and Nuermberger point out that individual studies are required by U.S. and global regulatory agencies. But, they say, regulators, pharmaceutical company officials and scientists must accelerate their efforts in evaluating the impact of new drugs - in combination form - if the spread of multidrug-resistant TB is to be contained.

Experts estimate that 2 billion people worldwide are infected with TB, 10 million of whom fall ill each year.

Explore further: Drug-resistant TB on rise in Africa

Related Stories

Drug-resistant TB on rise in Africa

November 10, 2006

Drug-resistant tuberculosis strains in Africa could kill millions of people and render useless expensive drugs protecting HIV-infected patients from TB.

New antibiotic drug combo to speed up treatment of tuberculosis

September 18, 2007

A team of tuberculosis (TB) experts at Johns Hopkins and in Brazil have evidence that substituting the antibiotic moxifloxacin in the regimen of drugs used to treat the highly contagious form of lung disease could dramatically ...

Drug-resistant TB blamed on Indian treatment flaws

March 23, 2012

(AP) -- India's inadequate government-run tuberculosis treatment programs and a lack of regulation of the sale of drugs that fight it are responsible for the spiraling number of drug-resistant cases that are difficult to ...

Recommended for you

Team makes Zika drug breakthrough

August 29, 2016

A team of researchers from Florida State University, Johns Hopkins University and the National Institutes of Health has found existing drug compounds that can both stop Zika from replicating in the body and from damaging ...

Zika virus may persist in the vagina days after infection

August 25, 2016

The Zika virus reproduces in the vaginal tissue of pregnant mice several days after infection, according to a study by Yale researchers. From the genitals, the virus spreads and infects the fetal brain, impairing fetal development. ...

In sub-Saharan Africa, cancer can be an infectious disease

August 26, 2016

In 1963, Irish surgeon Denis Parson Burkitt airmailed samples of an unusual jaw tumor found in Ugandan children to his colleague, Anthony Epstein, at Middlesex Hospital in London. Epstein, an expert in chicken viruses and ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.